SLS 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-11

• Our expenditures are subject to additional uncertainties, including the terms and timing of regulatory approvals. We may never succeed in achieving regulatory approval for any of our current or future product

• candidates. We may obtain unexpected results from our clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or target indications or focus on others. A change in the outcome of any of these variables with respect to the development of a product cand…

• •$0.6 million of increased external clinical trial expenses related to SLS009 driven by the timing of enrollment in our randomized Phase 2 clinical trial of newly diagnosed, front-line AML patients;

• Research and development expenses were $11.4 million for the six months ended June 30, 2026 compared to $7.1 million for the six months ended June 30, 2025.

• The increase in research and development expenses of approximately $4.3 million was primarily attributable to the following:

相对上期删除的文字 · 来源:10-Q · 2026-05-12

• In December 2020, we entered into an exclusive license agreement, or the 3D Medicines Agreement, with 3D Medicines Inc., or 3D Medicines, a China-based biopharmaceutical company developing next-generation immuno-oncology drugs, for the development and commercialization of GPS, as well as our next ge…

• and milestone payments under our license agreement with 3D Medicines, or the 3D Medicines Agreement, and a total of $191.5 million in potential future development, regulatory and sales milestones, not including future royalties, remains under the license agreement, which milestones are variable in n…

• Our expenditures are subject to additional uncertainties, including the terms and timing of regulatory approvals. We may never succeed in achieving regulatory approval for any of our current or future product candidates. We may obtain unexpected results from our clinical trials. We may elect to disc…

• •$0.2 million of decreased external clinical trial expenses related to SLS009 driven by the timing of patient enrollment as we commenced a randomized Phase 2 clinical trial of newly diagnosed, front-line AML patients at the end of the current period.

• Non-operating income of $0.8 million and $0.3 million during the three months ended March 31, 2026 and 2025, respectively, was related to interest income earned from our cash and cash equivalents.